References
- Faltermann S, Hettich T, Küng N, et al. Effects of the glucocorticoid clobetasol propionate and its mixture with cortisol and different class steroids in adult female zebrafish. Aquat Toxicol. 2019;218(2020):1–13.
- Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821–847.
- Allied Market Research. Anti-inflammatory therapeutics market analysis. [Internet]. 2020. [retrieved 2020 Aug 17] Available from: https://www.alliedmarketresearch.com/anti-inflammatory-therapeutics-market
- Allied Market Research. Anti-inflammatory therapeutics market is expected to reach $106.1 billion, globally, by 2020. [internet]. 2020. [retrieved 2020 Aug 17] Available from:https://www.alliedmarketresearch.com/press-release/anti-inflammatory-therapeutics-market.html
- Moore N, Duong M, Gulmez SE, et al. Pharmacoepidemiology of non-steroidal anti-inflammatory drugs. Therapie. 2019;74(2):271–277.
- Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs) [updated 2020 may 18]. in: statpearls [internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547742/
- Sostres C, Gargallo CJ, Arroyo MT, et al. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121–132.
- Walt R, Logan R, Katschinski B, et al. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986;327(8479):489–492.
- Brun J, Jones R. Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med. 2001;110(1A):12S–13S.
- Al-bayati NJ, Ewadh MJ, Ijam AH. Gastroprotective and antioxidant potential of montelukast against acetyl salicylic acid induced gastric ulcer model in male rabbits. Int J Curr Microbiol App Sci. 2015;4(5):80–89.
- Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol. 2013;48(7):830–838.
- Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15(SUPPL 3):1–8.
- Atchison JW, Herndon CM, Rusie E. NSAIDs for musculoskeletal pain management:current perspectives and novel strategies to improve safety. J Manag Care Pharm. 2013 Nov-Dec;19(9 Suppl A):S3–19. PMID: 24261788.
- Wang X, Wang L, Yu X, et al. Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice. Int Immunopharmacol. 2019;75:1–10.
- Mendes RT, Stanczyk CP, Sordi R, et al. Selective inhibition of cyclooxygenase-2: risks and benefits. Rev Bras Reumatol. 2012 Oct;52(5):774–782. São Paulo.
- Raafat K, El-Darra N, Saleh FA. Gastroprotective and anti-inflammatory effects of Prunus cerasus phytochemicals and their possible mechanisms of action. J Tradit Complement Med. 2019;10(2020):345–353.
- Shah V, Lyford G, Gores G, et al. Nitric oxide in gastrointestinal health and disease. Gastroenterology. 2004;126(3):903–913.
- Stamler JS, Singel DJ, Loscalzo J. Bioquímica do óxido nítrico e suas formas ativadas por redox. Science 1992;258(5090):1898–1902.
- Buca BR, Popa EG, Crețeanu A, et al. A new therapeutic strategy: the nonsteroidal anti-inflammatory drugs nitric oxide donors. Farmacist Ro. 2018;1(180):22–25.
- Tang Q, Zhang W, Zhang C, et al. Oxymatrine loaded nitric oxide-releasing liposomes for the treatment of ulcerative colitis. Int J Pharm. 2020;586:119617.
- Garvey DS, Letras LG, Renfroe HB, et al. inventors; Nitromed INC, assignee. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs. United States patent US 5703073A. 1997 Dec 30.
- Earl RA, Ezawa M, Fang X, et al. inventors; Nicox SA, assignee. Nitrosated nonsteroidal antiinflammatory compound, composition and method of use. Japan patent JP 2010280665A. 2010 Dec 16.
- García-Ortiz A, Serrador JM. Nitric Oxide Signaling in T Cell-Mediated Immunity. Trends Mol Med. 2018;24(4):412–427.
- Korhonen R, Lahti A, Kankaanranta H, et al. Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy. 2005;4(4):471–479.
- Sondhi SM, Rajvanshi S, Johan M, et al. Anti-inflammatory, analgesic and antiamoebic activity evaluation of pyrimido[1,6-a]benzimidazole derivatives synthesized by the reaction of ketoisothiocyanates with mono and diamines. Eur J Med Chem. 2002;37(10):835–843.
- Qian Y, Zhang Y, Zhong P, et al., Inhibition of inflammation and oxidative stress by an imidazopyridine derivative X22 prevents heart injury from obesity. J Cell Mol Med. 2016;20(8): 1427–1442.
- Morini G, Grandi D, Sasse A, et al. Gastroprotective activity of the novel histamine H3-receptor agonist FUB 407. Inflamm Res. 2001;50(SUPPL. 2):116–117.
- Clark RB, Ferreira SH, Mehta NB, et al. inventors; Wellcome found, assignee. Nonulcerogenic antiinflammatory compsns. - contain e.g. acetyl-salicylic acid plus a (benz)imidazole deriv. to prevent formation of gastric lesions. France patent FR 2319346. 1977 February 25.
- Hobrecker F. Ber. Dtsch Chem Ges. 1872;5:290.
- Keri RS, Hiremathad A, Budagumpi S, et al. Comprehensive review in current developments of benzimidazole-based medicinal chemistry. Chem Biol Drug Des. 2015;86(1):799–845.
- Boggu PR, Venkateswararao E, Manickam M, et al. Exploration of SAR for novel 2-benzylbenzimidazole analogs as inhibitor of transcription factor NF-κB. Archiv Pharm Res. 2017;40(4):469–479.
- Boggu PR, Venkateswararao E, Manickam M, et al. Exploration of 2-benzylbenzimidazole scaffold as novel inhibitor of NF-κB. Bioorg Med Chem. 2016;24(8):1872–1878.
- Takagi M, Nagano Y, Nanae D, et al. inventors; Nippon Soda Co., assignee. Antiinflammatory analgesic agent and agent for treatment of allergic disease. Japan patent JP 2006104198. 2006 Apr 20.
- Belliotti TR, Connor DT, Kostlan CR, inventors; Warner Lambert Co, assignee. Substituted heteroaryl analogs of 4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents. United States patent US 5432181A. 1995 Jul 11.
- Ghatak S, Vyas A, Misra S, et al. Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities. Bioorg Med Chem Lett. 2014;24(1):317–324.
- Liaras K, Fesatidou M, Geronikaki A. Thiazoles and thiazolidinones as COX/LOX inhibitors. Molecules 2018;23(3):1–21.
- Schrier DJ, U Nangst PC, Connor DT, et al. Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J Med Chem. 1994;37(2):322–328.
- Baltina LA, Davydova VA, Lazareva DN, et al. inventors; inst orch khim ufim nauchnogo, assignee. beta-glycyrrhizic acid glycopeptide with l-glutamic acid dibutyl ether showing antiinflammatory and antiulcer activity. Russia patent RU 2024548C1. 1994 Dec 26
- Tolstikov GA, Baltina LA, Davydova VA, et al. inventors; inst orch khim ural otdel ran, assignee. Amide beta glycirrhizic acid with phenylboron acid showing antiinflammatory and antiulcerous activity. Russia patent RU 2024548C1. 1995 October 04.
- Guaratini MTG, Lima CAH, Solferini VN, inventors; universidade estadual de campinas - unicamp (BR/SP), assignee. Extrato diclorometânico de “Bidens alba l.” com atividades antlulcerogênicas dos sesquiterpenos e poliacetilenos. Brazil patent PI 0401592–4. 2005 November 29.
- Jalilzadeh-Amin G, Najarnezhad V, Anassori E, et al. Antiulcer properties of glycyrrhiza glabra L. Extract on experimental models of gastric ulcer in mice. Iran J Pharm Res. 2015;14(4):1163–1170.
- Aslam B, Awan T, Javed I, et al. Gastroprotective and antioxidant potential of Glycyrrhiza glabra on experimentally induced gastric ulcers in albino mice. In Int J Curr Microbiol App Sci. 2015;4:2.
- Lans CA. Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus. J Ethnobiol Ethnomed. 2006;2(1):1–11.
- Ong PL, Weng BC, Lu FJ, et al. The anticancer effect of protein-extract from Bidens alba in human colorectal carcinoma SW480 cells via the reactive oxidative species- and glutathione depletion-dependent apoptosis. Food Chem Toxicol. 2008;46(5):1535–1547.
- Anzalone S, inventor; anzalone, sergio; medosan ricerca S.R.L., assignee. Use of amtolmetin guacyl for the production of anti-inflammatory drugs for intestinal inflammations. Italy patent WO 0032188A2. 2000 June 08.
- Tubaro E, Belogi L, Mezzadri CM, et al. Impact on the bowel of amtolmetin guacyl, a new gastroprotective non-steroidal anti-inflammatory drug. Eur J Pharmacol. 2003;467(1–3):173–183.
- Garg A, Shoeb A, Moodahadu LS, et al. Amtolmetin: a Reappraisal of NSAID with Gastroprotection. Arthritis 2016;2016:1–5.
- Crawford TC, Keely SL, Larson DL, et al. inventors; Pfizer, assignee. Antiinflammatory compositions and methods. Canada patent CA 1249521A. 1989 Jan 31.
- Zhao J, Fan Y, Ye W, et al. The protective effect of teprenone on aspirin-related gastric mucosal injuries. Gastroenterol Res Pract. 2019;2019:6532876.
- Brogden RN, Heel RC, Speight TM, et al. Tolmetin: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs 1978;15(6):429–450.
- Ramadan AA, Elbakry AM, Esmaeil AH, et al. Pharmaceutical and pharmacokinetic evaluation of novel rectal mucoadhesive hydrogels containing tolmetin sodium. J Pharm Investig. 2017;48(6):673–683.
- Villa AL, Ceneviva R, Viaro F, et al. The cytoprotective effect of a nitric oxide donor drug on gastric mucous membrane of rats treated with ketoprofen, a non-steroidal anti-inflammatory drug. Arq Gastroenterol. 2006;43(3):233–237.
- Bilgiç M inventor; yildrz teknik universitesi davutpa§a kampusu teknoloji geli§tirme bblgesi d 1blok k.3 esenler/istanbul (TR) assignee. A pharmaceutical composition comprising prucalopride and a proton pump inhibitor. Turkey Patent WO2020022974A3. 2020 Jan 31.
- Camilleri M, Deiteren A. Prucalopride for constipation. Expert Opin Pharmacother. 2010 Feb;11(3):451–461.
- Bhandari A, Bourne G, Cheng X, et al. assignee. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases. US 20190300590 A1. Oct 3, 2019.
- Mortel MR. Emer J: prospective new biologic therapies for psoriasis and psoriatic arthritis. J Drugs Dermatol. 2010;9:952–963.
- Oliveira A, Cipriani T, Côrtes L, et al., assignee. Obtenção de polissacarídeos do balsamo (sedum dendroideum) e o uso dos polissacarídeos como agentes gastroprotetores, anti-inflamatórios e moduladores da função imune em humanos. BR 10 2017 011953 0 A2. Dez 26, 2018.